The article examines how federal cannabis rescheduling is a significant issue, especially regarding the potential policies of a Trump administration. Currently classified as a Schedule I drug, cannabis faces numerous restrictions, which could change if it were reclassified to Schedule II or III. This change could facilitate easier research and banking for cannabis businesses. Trump's historical approach to cannabis has been mixed; he has shown some support for state autonomy in cannabis laws while simultaneously undermining industry regulations. Current public support for cannabis legalization could pressure any future Trump administration to adopt a more progressive stance on the issue.
Trump's past actions show a somewhat flexible approach towards cannabis policy, indicating a potential openness to rescheduling under public pressure and state initiatives.
Rescheduling cannabis could lead to significant benefits, such as improved research opportunities and federal banking access for dispensaries, though it’s not the same as outright legalization.
Collection
[
|
...
]